Adenocarcinoma | selleckchem.com

Chemotherapy

Platinum-based: Cisplatin; Carboplatin; Nedaplatin

Alkaloids: Vinorelbine ditartrate; Paclitaxel; Docetaxel

Antimetabolites: Pemetrexed; Gemcitabine

TOPO Inhibitors: Irinotecan

RET-Targeted

Selective RET Inhibitors: LOXO-292; Pralsetinib

Non-Selective RET Inhibitors: Cabozantinib; Vandetanib; E7080; Regorafenib

BRAF-Targeted

First-Generation (Type I) BRAF Inhibitors: PLX4032; Dabrafenib; LGX818

Next-Generation (Type II) BRAF Inhibitors: AZ 628; LY3009120

ROS1-Targeted

First-Generation ROS1-TKIs: PF-02341066

Second-Generation ROS1-TKIs: Ceritinib; Repotrectinib

Third-Generation ROS1-TKIs: Lorlatinib

MET-Targeted

Type I MET-TKIs: PF-02341066; Capmatinib; Tepotinib; Savolitinib

Type II MET-TKIs: Cabozantinib; Merestinib

Type III MET-TKIs: Tivantinib

KRAS G12C-Targeted

ALK-Targeted

First-Generation ALK-TKIs: PF-02341066

Second-Generation ALK-TKIs: Ceritinib; Alectinib; Brigatinib; Ensartinib dihydrochloride

Third-Generation ALK-TKIs: Lorlatinib

EGFR-Targeted

First-Generation EGFR-TKIs: Erlotinib; Gefitinib; Lapatinib; Icotinib

Second-Generation EGFR-TKIs: Afatinib; Dacomitinib; Neratinib; Poziotinib

Third-Generation EGFR-TKIs: AZD9291; Mobocertinib; Rociletinib; Olmutinib; Nazartinib; Furmonertinib Mesylate; Almonertinib; Lazertinib

Fourth-Generation EGFR-TKIs: EAI045

Anti-EGFR Antibodies: Cetuximab; Panitumumab; Necitumumab

Compound Library

FDA-approved Anticancer Drug Library

Anti-cancer Compound Library

Anti-cancer Compound Library-Ⅱ

Anti-cancer Metabolism Compound Library

Cambridge Cancer Compound Library

FDA-approved Drug Library

ADC

c-Met: Telisotuzumab vedotin

HER2: Trastuzumab-Emtansine（T-DM1）; Trastuzumab-deruxtecan

HER3: Patritumab deruxtecan

Anti-Angiogenesis

Immune Checkpoint Inhibitors

PD-1: Pembrolizumab; Camrelizumab; Sintilimab; Nivolumab; Cemiplimab

PD-L1: Atezolizumab; Durvalumab; Avelumab

CTLA-4: Ipilimumab; Tremelimumab

HER2-Targeted

Pan-HER TKIs: Afatinib; Neratinib; Dacomitinib

Selective HER2 TKIs: Pyrotinib dimaleate; Poziotinib; (S)-Sunvozertinib

Anti-HER2 Antibodies: Trastuzumab; Pertuzumab